PROSTest is a multigenomic liquid biopsy that detects prostate cancer using a single whole blood sample, providing advanced molecular insight without the need for tissue or urine collection.
Developed by Wren Laboratories, PROSTest analyzes the expression of 27 androgen receptor–regulated genes across circulating tumor-derived components (cfRNA, CTCs, exosomes, tumor-educated platelets, and immune cells). Results are reported as a 0–100% likelihood score, enabling physicians to more confidently guide biopsy decisions, monitor disease activity, and assess treatment response.
PROSTest Benefits
Designed for clinical impact, PROSTest offers physicians a high-performance tool for prostate cancer detection and monitoring.
-
Multianalyte Detection
Captures gene expression signals from multiple circulating tumor sources (cfRNA, CTCs, exosomes, TEPs, immune cells), offering a broader view of disease biology. -
Whole-Blood Convenience
A single 2 mL blood draw. No urine collection, DRE prep, or tissue required. Samples remain stable during ambient shipping with no pre-processing needed. -
Actionable Results
Clear, binary interpretation with a validated 50% cutoff score makes it easy to stratify patients and guide next steps. Scores correlate with Gleason grade, PSA kinetics, and MRD status. -
Clinical Versatility
Applicable across key care pathways: biopsy triage, active surveillance, post-treatment monitoring, and radioligand response assessment.
How to Order PROSTest
Providers may order tests through Wren Laboratories here.